Structure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory Antibody

• DOI: 10.1371/journal.ppat.0030138
• Publication Date: 2007-09-26T17:16:59Z
• Authors: Andrew M Coley; Aditi Gupta; Vince J Murphy; Tao Bai; Hanna Kim; Robin F Anders; Michael Foley; Adrian H Batchelor
• Keywords: Models, Molecular; 0301 basic medicine; QH301-705.5; Protozoan Proteins; Antigens, Protozoan; Enzyme-Linked Immunosorbent Assay; Antigen-Antibody Complex; Crystallography, X-Ray; 110705 Humoural Immunology and Immunochemistry; Immunoglobulin kappa-Chains; 03 medical and health sciences; Malaria Vaccines; Animals; Humans; Biology (General); Antibodies, Monoclonal; Membrane Proteins; 0605 (four-digit-FOR); RC581-607; Malaria; 3. Good health; Binding Sites, Antibody; 060599 Microbiology not elsewhere classified; Immunologic diseases. Allergy; Crystallization; Research Article

Identifying functionally critical regions of the malaria antigen AMA1 (apical membrane antigen 1) is necessary to understand the significance of the polymorphisms within this antigen for vaccine development. The crystal structure of AMA1 in complex with the Fab fragment of inhibitory monoclonal antibody 1F9 reveals that 1F9 binds to the AMA1 solvent-exposed hydrophobic trough, confirming its importance. 1F9 uses the heavy and light chain complementarity-determining regions (CDRs) to wrap around the polymorphic loops adjacent to the trough, but uses a ridge of framework residues to bind to the hydrophobic trough. The resulting 1F9-AMA1-combined buried surface of 2,470 A(2) is considerably larger than previously reported Fab-antigen interfaces. Mutations of polymorphic AMA1 residues within the 1F9 epitope disrupt 1F9 binding and dramatically reduce the binding of affinity-purified human antibodies. Moreover, 1F9 binding to AMA1 is competed by naturally acquired human antibodies, confirming that the 1F9 epitope is a frequent target of immunological attack.